Salomé N, Stemmelin J, Cohen C, Griebel G
Department of Psychopharmacology, Sanofi-Aventis, 31 av Paul Vaillant-Couturier, 92220 Bagneux, France.
Pharmacol Biochem Behav. 2006 Apr;83(4):533-9. doi: 10.1016/j.pbb.2006.03.013. Epub 2006 Apr 19.
There is a growing interest in the potential anxiolytic- and antidepressant-like effects of compounds that target neurokinin receptors. Since the structure and the pharmacology of the human neurokinin receptor resembles that of gerbils, rather than that of mice or rats, we decided to investigate the anxiolytic- and /or antidepressant-like effects of NK1 (SSR240600), NK2 (saredutant) and NK3 (osanetant) receptor antagonists in gerbils. It was found that saredutant (3-10 mg/kg, p.o.) and osanetant (3-10 mg/kg, p.o.) produced anxiolytic-like effects in the gerbil social interaction test. These effects were similar to those obtained with the V1b receptor antagonist SSR149415 (3-10 mg/kg, p.o.), diazepam (1 mg/kg, p.o.) and buspirone (10 mg/kg, p.o.). Fluoxetine and SSR240600 were devoid of effects in this test. In the tonic immobility test in gerbils, saredutant (5-10 mg/kg, i.p.) and osanetant (5-10 mg/kg, i.p.) produced similar effects to those observed with fluoxetine (7.5-15 mg/kg, i.p.), SSR149415 (10-30 mg/kg, p.o.) and buspirone (3 mg/kg, i.p.). Diazepam and SSR240600 were inactive in this paradigm. In conclusion, the present study indicates further that NK2 and NK3 receptor antagonists may have therapeutic potential in the clinical management of anxiety and depression.
针对神经激肽受体的化合物潜在的抗焦虑和抗抑郁样作用正受到越来越多的关注。由于人类神经激肽受体的结构和药理学与沙鼠相似,而非小鼠或大鼠,我们决定研究NK1(SSR240600)、NK2(沙瑞肽坦)和NK3(奥沙奈坦)受体拮抗剂在沙鼠中的抗焦虑和/或抗抑郁样作用。结果发现,沙瑞肽坦(3 - 10毫克/千克,口服)和奥沙奈坦(3 - 10毫克/千克,口服)在沙鼠社交互动试验中产生了抗焦虑样作用。这些作用与V1b受体拮抗剂SSR149415(3 - 10毫克/千克,口服)、地西泮(1毫克/千克,口服)和丁螺环酮(10毫克/千克,口服)所产生的作用相似。氟西汀和SSR240600在此试验中无作用。在沙鼠的强直性不动试验中,沙瑞肽坦(5 - 10毫克/千克,腹腔注射)和奥沙奈坦(5 - 10毫克/千克,腹腔注射)产生的作用与氟西汀(7.5 - 15毫克/千克,腹腔注射)、SSR149415(10 - 30毫克/千克,口服)和丁螺环酮(3毫克/千克,腹腔注射)所观察到的作用相似。地西泮和SSR240600在此范式中无活性。总之,本研究进一步表明,NK2和NK3受体拮抗剂在焦虑和抑郁的临床管理中可能具有治疗潜力。